Navigation Links
New once-a-week treatment for type 2 diabetes developed by Mount Sinai researcher
Date:9/7/2008

(Toronto, ON, September 8, 2008) In a study published by the Lancet journal today, Toronto researcher Dr. Daniel Drucker reported that a new once-weekly treatment for type 2 diabetes could replace the more common twice-daily injection.

"Over two million Canadians have diabetes," said Dr. Daniel Drucker, clinician-scientist and Senior Investigator at the Samuel Lunenfeld Research Institute of Mount Sinai Hospital. "There is currently no available therapy for type 2 diabetes that patients can receive once a week."

The new treatment, Exenatide once weekly is the first in a new class of long-acting medications that mimic the action of GLP-1 (glucagon-like peptide), a naturally occurring hormone that is produced in the gut after eating. The report compared outcomes for patients self-injecting Exenatide once weekly against results from the conventional 14 injections a week, as in the currently available version of the drug known as Exenatide (Byetta).

In an international multicentre 6-month clinical trial involving 300 eligible patients, 75 per cent of study subjects who received the once-weekly Exenatide got their diabetes under control as defined by reaching target glucose levels. Patients treated with Exenatide once weekly also experienced fewer side effects, had no increased risk of hypoglycemia (decrease in blood sugars) and saw reductions in body weight.

Dr. Drucker has studied the gut hormone GLP-1 for over 20 years. Multiple drugs based on GLP-1 action are under active clinical development, and the new once-weekly treatment is expected to undergo Canadian regulatory review as early as 2009.

"Biomedical research reaches patients and improves lives," said Dr. Jim Woodgett, Director of Research at the Samuel Lunenfeld Research Institute. "Dr. Drucker is a world-expert in the development of peptide hormone-based therapies for the treatment of human disease and this is an excellent example of moving discovery
'/>"/>

Contact: Nikki Luscombe
luscombe@lunenfeld.ca
416-586-4800 x2046
Samuel Lunenfeld Research Institute
Source:Eurekalert

Page: 1 2

Related biology news :

1. Landmark study opens door to new cancer, aging treatments
2. Common treatment to delay labor decreases preterm infants risk for cerebral palsy
3. UC Davis researchers define characteristics, treatment options for XXYY syndrome
4. Why a common treatment for prostate cancer ultimately fails
5. Biodegradable polymers show promise for improving treatment of acute inflammatory diseases
6. Childrens national co-leads nationwide study of landmark sickle cell treatment
7. Potatoes may hold key to Alzheimers treatment
8. Blood pressure response to daily stress provides clues for better hypertension treatment
9. Genes newly explained effect on height may change tumor disorder treatment
10. Songbirds may hold key to advances in treatment of brain degeneration
11. Treatment corrects severe insulin imbalance in animal studies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... to encourage healthier spending habits? A new study by ... by tracking the purchasing records in a supermarket chain ... nutritional value of foods for sale. , The researchers, ... and Brian Wansink PhD, author of Slim by Design ... Supermarkets in the Northeastern United States between January 2005 ...
(Date:8/19/2014)... the world, leprosy and tuberculosis live side-by-side. Worldwide ... per year, with nearly all of them occurring ... vaccine Bacille Calmette-Guerin, or BCG, provides only partial ... more potent vaccine is needed to combat both ... weapon against both diseases., In a study published ...
(Date:8/19/2014)... (Boston) Some infants born with neonatal abstinence ... a more difficult time going through withdrawal than ... understood. While genetic and epigenetic (when genes are ... identified as potential factors, researchers at Boston University ... (BMC) conducted a first of its kind study ...
Breaking Biology News(10 mins):New vaccine shows promise as stronger weapon against both tuberculosis and leprosy 2In-utero methadone, Subutex exposure could alter gene expression, cause severe Neonatal Abstience Syndrome 2
... American scientists have rediscovered a highly distinctive mammal C a ... years ago. Furthermore, it has never before been discovered in ... extinct. , The greater dwarf cloud rat (Carpomys melanurus) has ... eyes, small rounded ears, a broad and blunt snout, and ...
... throughout the sciences in the study of biological, technological, ... to visualize or understand. In a May 1 ... links in networks, Santa Fe Institute (SFI) researchers Aaron ... real-world networks can be understood as a hierarchy of ...
... Iowa and HOUSTON, Texas The first year ... at Iowa State University (ISU) has supported 26 ... to further diversify Americas sources of energy and ... third-largest integrated energy company in the United States, ...
Cached Biology News:Dwarf cloud rat rediscovered after 112 years 2Dwarf cloud rat rediscovered after 112 years 3Nature paper describes technique for extracting hierarchical structure of networks 2Iowa State-ConocoPhillips collaboration advances 26 research projects in first year 2
(Date:8/19/2014)... (PRWEB) August 19, 2014 XenoTech ... fast and cost-effective metabolite production from bioactive small ... chemistry platform, the technology enables convenient and timely ... According to XenoTech’s Vice President of Commercial Operations, ... for assessing clinical risk can be measured directly ...
(Date:8/19/2014)... , Aug. 19, 2014   Synthetic ... company developing novel anti-infective biologic and drug programs ... diseases, announced today that its novel C. ... the 54 th Interscience Conference on Antimicrobial ... Washington D.C. Synthetic ...
(Date:8/18/2014)... 2014) -- A new therapy developed by researchers ... College of Medicine and Columbia University Medical Center ... interventional cardiovascular disease treatment. , The researchers ... molecular therapy could selectively inhibit blood vessel re-narrowing ... procedure using a balloon catheter to open narrowed ...
(Date:8/18/2014)... with unprecedented efficiency and data storage may ... built-in electric polarizations to read and write ... popular data-driven technology. But ferroelectrics must first ... a curious habit of "forgetting" stored data. ... Department of Energy,s Brookhaven National Laboratory have ...
Breaking Biology Technology:Beyond Metabolite Identification, Testable Quantities Now Offered by XenoTech 2Beyond Metabolite Identification, Testable Quantities Now Offered by XenoTech 3Synthetic Biologics Announces Late-Breaking Poster Presentation for C. difficile Program at 54th ICAAC 2Synthetic Biologics Announces Late-Breaking Poster Presentation for C. difficile Program at 54th ICAAC 3Synthetic Biologics Announces Late-Breaking Poster Presentation for C. difficile Program at 54th ICAAC 4Selective therapy may improve artery repair after interventional cardiovascular procedures 2Selective therapy may improve artery repair after interventional cardiovascular procedures 3Promising ferroelectric materials suffer from unexpected electric polarizations 2Promising ferroelectric materials suffer from unexpected electric polarizations 3Promising ferroelectric materials suffer from unexpected electric polarizations 4
... YORK, April 17 The market for congestive ... billion in 2007, and is,expected to reach $30 ... by,Kalorama Information, Congestive Heart Failure: Major World Markets, ... three factors: an,increased incidence of CHF, the application ...
... JENA, Germany, April 17 Occlutech GmbH, the leading,European ... a recent news release., In a news release ... opinion from AIPPI the European "Association for the Protection,of ... of,certain European IP held by AGA Medical., AIPPI ...
... April 17 BioMed Realty Trust, Inc.,(NYSE: BMR ... of 5,700,000,shares of common stock at $25.50 per share. ... 22, 2008. Gross proceeds from the offering will be,approximately ... of the,offering to repay a portion of the outstanding ...
Cached Biology Technology:Genomics Likely to Replace Traditional Drug Therapies in Treating CHF 2Occlutech Clarifies Statement Regarding Favourable Opinion Obtained From AIPPI With Regard to Patents Held by AGA Medical 2BioMed Realty Trust Prices Public Offering of 5,700,000 Shares of Common Stock 2BioMed Realty Trust Prices Public Offering of 5,700,000 Shares of Common Stock 3
Whole blood is collected from healthy pigs (mixed breed, either sex) at the time of slaughter, refrigerated within 6 hours, processed within 24 hours and frozen at -20ºC....
... Rhesus Serum • Rhesus serum is collected ... 5-7 years of age. Available Anticoagulants: ... Heparin (Na) N-06: K2EDTA N-08: ... N-03: Alsevers N-05: ACD ...
Reacts with MBP from human, bovine and rat, epitope 129-138. Reacts weakly with rabbit. Does not react with guinea pig....
... DCTD_HUMAN GI Number: 4503277 ... Description: FUNCTION: Supplies the nucleotide ... dCMP + H 2 O = ... Homohexamer. SIMILARITY: Belongs to the Diseases: ...
Biology Products: